Barry M. Kaplan is the head of the Northwest litigation group of Wilson Sonsini Goodrich & Rosati. Barry has broad experience in securities and corporate governance litigation, class action defense, SEC and internal corporate investigations, and complex commercial litigation. He was described in the 2017 edition of Chambers USA: America’s Leading Lawyers for Business as “the dean of securities litigation in Seattle.”
For 30 years, Barry has represented many of the public companies and individuals sued in shareholder class actions and related corporate litigation both in the Northwest and across the country, including The Boeing Company, Micron Technology, Sterling Financial Corporation, Alaska Air, Starbucks, Costco, and Coinstar. Barry was lead counsel for the former CEO of Washington Mutual, Inc. in the various shareholder lawsuits and related litigation that followed the seizure and sale of WaMu to JPMorgan Chase. He has special expertise in representing public biotech companies around the country and, among others, has represented Immunex, Dendreon, Inspire Pharmaceuticals, Pozen, Chelsea Therapeutics, Atossa Genetics, Seattle Genetics, Novan, Globus Medical and Cell Therapeutics.
Barry is a frequent writer and speaker on securities litigation and corporate law and governance topics, and teaches a course on securities and shareholder litigation at the University of Washington School of Law. Along with partner Greg Watts, Barry is the author of “Directors’ and Officers’ Liability, 3rd Edition” published by PLI. He also co-authored the leading treatise on Washington corporate law, published by LexisNexis.
Best Lawyers in America named Barry the 2012 Securities Litigator of the Year for Seattle—the first time that this recognition had been given to a Seattle securities litigator. He was again given this honor in 2016.